Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
This real-world study of patients with CM demonstrated that adding atogepant to onabotulinumtoxinA as a combination preventive treatment for CM was effective by providing an additional reduction in MHDs over ~ 3 and ~ 6 months of combination treatment. Safety results were consistent with the known safety profiles of onabotulinumtoxinA and atogepant, with no new safety signals identified.
Authors
- Brett Dabruzzo (ORCID: https://orcid.org/0009-0008-3048-2633)
- Andrew Blumenfeld (ORCID: https://orcid.org/0000-0003-0851-4914)
- Brian Jenkins
- László Mechtler
- Olivia Hughes (ORCID: https://orcid.org/0000-0002-6607-1923)
- Merle L. Diamond
- Christopher Rhyne (ORCID: https://orcid.org/0000-0002-4540-4485)
- Lisa Cook
- Aubrey Manack Adams
Institutions
- University of California, Los Angeles (US)
- Norton Healthcare (US)
- AbbVie (United States) (US)
- Quantum Group (United States) (US)
- Pain and Headache Center (US)
- Diamond Headache Clinic (US)
- Dent Neurologic Institute (US)
- Surgical Associates of Neenah (US)
Publication Details
- Journal
- Pain and Therapy
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1007/s40122-024-00649-8
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- AbbVie